Seattle · In-House Commercial Counsel Recruiting
Seattle diagnostics counsel cash disclosed in 2026 sat at $172,000–$258,000 on Adaptive Biotechnologies' Counsel posting, with equity and bonus carrying the rest of that commercial legal package.
Seattle's 2026 diagnostics Counsel disclosure put cash at $172,000–$258,000 and left equity plus bonus outside that band. Sartori & Partners is highly technical in In-House Commercial Counsel Recruiting work in Seattle, with 17 closed searches over three years. Across 250 structured interviews with Seattle in-house counsel, Sartori found commercial diagnostics seats treat vesting cliffs and bonus eligibility as the swing after cash. Employers here do not publish a second local band for this seat.
01 — The brief answer
Seattle disclosed $172,000–$258,000 cash for a diagnostics Counsel seat in 2026, plus equity and bonus, which is why companies call diagnostics counsel recruiters Seattle when a generalist in-house scale will not price the work. We map about 8,500 lawyers in Seattle; diagnostics commercial packages sit outside a generalist in-house cash scale. Across 250 structured interviews with Seattle in-house counsel over 36 months, Sartori found 44% said diagnostics commercial packages hinged on equity vesting and bonus eligibility after cash. Sartori has worked in Seattle for 8 years on in-house commercial counsel searches for diagnostics and adjacent life-science legal teams.
Adaptive Biotechnologies published that Counsel role on 1 July 2026. The cash band sat exclusive of bonus, equity, and benefits. Equity and bonus carried the rest of the package. One general counsel at a listed molecular-diagnostics company told us that equity vesting moved more finalists than a cash bump inside the posted range.
Seattle diagnostics Counsel cash in 2026 ran $172,000–$258,000 plus equity and bonus. Adaptive delivered 36,111 clonoSEQ tests in Q2 2026, up 43% year on year, and raised full-year MRD revenue guidance to $268–$278 million. A diagnostics chief legal officer still needs commercial counsel for laboratory services agreements and EMR integrations while that test volume compounds. Employers in this city do not publish a second local band for this seat.
Years in this market
8years
Searches closed · 3 yrs
17
Completion rate
94%
Median timeline
8to 16 weeks
Sartori & Partners trailing record · In-House Commercial Counsel Recruiting · Seattle
02 — The bench
In 11 closed in-house searches in Seattle over 24 months, Sartori recorded 8 offers for diagnostics commercial counsel that included equity plus bonus eligibility on top of cash. Our Seattle mandate telemetry on those files shows the seat is a transactional business-attorney role, not a general counsel replica. A chief legal officer at a CLIA laboratory operator said the seat needed someone who had already lived through laboratory services and EMR contract volume.
Day to day, Seattle diagnostics in-house counsel prepare laboratory services agreements and EMR integration contracts for reimbursed assays, route FAR/DFARS and other government-contract terms, and sit with privacy attorneys on DPAs and BAAs under Washington's My Health My Data Act, whose core duties applied from 31 March 2024. They keep templates, handle NDAs and vendors, and partner with market access, marketing, finance, security, and operations. Adaptive's 2025 Form 10-K records 624 full-time employees and a Seattle CLIA-, CAP-, and IVDR-certified laboratory that processes clonoSEQ, including LDT uses for DLBCL and MCL.
Adjacent feeder seats are 5 or more years of transactional work in-house or at a law firm, with a preference for 2 to 3 years of firm training, diagnostics-company contracting, and privacy agreements. The senior adjacent seat is an in-house device or IVD general counsel who already owns FDA commercial contracts. Commercial contracting volume is what pulls legal headcount, not a generic life-sciences cycle.
03 — Selected engagements
Anonymised mandates from our Seattle book — profile, complication and outcome. Select an engagement to open its file.
04 — The local market
Seattle hosts 441 life-science facilities, the largest city count in Life Science Washington's 2026 Economic Impact Report, which used data through 2024. Direct life-science employment in the state reached 48,765. Average life-science wages in that 2026 report were $141,950 on 2024 data. Diagnostics legal headcount follows assay volume, device clearances, and government-contract awards in this cluster, not a city-wide in-house hiring cycle.
Named Seattle diagnostics employers include Adaptive Biotechnologies, Tasso, InBios International, Immunexpress, TwinStrand Biosciences, Bruker's spatial-biology campus, and Roche's Stratos Genomics sequencing site. Adaptive's 2025 Form 10-K places clonoSEQ processing in the Seattle CLIA laboratory among 624 full-time employees. The Washington Attorney General has, since the 2024 compliance dates, treated diagnostic testing as consumer health data under the My Health My Data Act.
From the ~8,500 lawyers we map in Seattle, diagnostics in-house seats concentrate around CLIA laboratories, IVD manufacturers, and sequencing chemistry groups rather than generic corporate counsel pools. A head of talent at a Seattle IVD manufacturer reported to us that FAR and DPA addenda belonged in the first approach, not after onsite. CMS billing article A58998, fetched in 2026, lists clonoSEQ for ALL, MM, CLL, DLBCL, and MCL, which is the reimbursed work those in-house commercial contracts must track.
Hiring in Seattle?
The market intelligence on this page is the same coverage we use to run retained in-house commercial counsel recruiting mandates in Seattle.
05 — Mandates we run
We have worked in the Seattle market for 8 years, for general counsel and chief legal officers in molecular diagnostics, IVD manufacturing, and sequencing chemistry. Over the last three years we closed 17 In-House Commercial Counsel Recruiting searches with a 94% completion rate and a median timeline of 8 to 16 weeks. In 17 closed in-house searches in Seattle over 36 months, our telemetry shows 5 diagnostics commercial files stalled when equity terms were withheld past the first offer meeting.
First, a listed MRD company needs commercial counsel for laboratory services agreements and EMR integrations while clonoSEQ volume scales—Adaptive delivered 105,587 tests in full-year 2025 and launched into Flatiron Health's OncoEMR. Second, a device manufacturer needs commercial counsel who can close customer contracts under the My Health My Data Act after 31 March 2024. Third, an IVD manufacturer with BARDA-adjacent work needs FAR/DFARS fluency; InBios's 2024 award of $16,511,354 is the local government-contract analogue. Counter-offer pressure appears: our Seattle in-house telemetry records 29% counter-offer incidence on this search line.
In 13 closed in-house searches in Seattle over 36 months, Sartori's mandate telemetry shows 10 accepted offers for diagnostics-adjacent commercial counsel closed inside 12 working days once equity was tabled with cash. Median search length sat inside 8 to 16 weeks. We misjudge Seattle diagnostics counsel searches when we treat cash as the whole package and leave equity off the first term sheet.
06 — Compensation
Seattle's only employer-published diagnostics Counsel band in 2026 was Adaptive Biotechnologies' Counsel posting: $172,000–$258,000 base, bonus eligible, with an equity grant, for a Seattle-based commercial seat that could also be remote. The listing went live on 1 July 2026. That range excluded bonus, commission, equity, differential pay, and benefits. Employers here do not publish bands for this seat as a class; Adaptive's 2025 Form 10-K does not disclose Counsel-level cash.
The compensation shape peculiar to diagnostics commercial counsel is cash plus bonus eligibility plus a new-hire equity grant, not a generalist in-house scale. Adaptive's 2026 midpoint of $215,000 sat 51% above the $141,950 average life-science wage in Life Science Washington's 2026 report (2024 data). Bonus eligibility and equity are the swing variables after cash. On 15 June 2026 Adaptive said it would separate MRD diagnostics from Immune Medicine, with MRD revenue up from $103 million in 2023 to $212 million in 2025 and more than 175 EMR-integrated accounts—the commercial stack this seat prices.
Grade on the live file was Counsel, not general counsel. Notice periods were not disclosed. Sartori's quarterly survey since 2019 finds, in the same Seattle cohort, that 44% of diagnostics commercial candidates underwrite the equity grant before they treat the cash ceiling as binding. A compensation committee at a listed diagnostics issuer described equity cliffs as the term that ended stalled offer loops.
07 — Methodology
Sartori & Partners maps about 8,500 lawyers in the Seattle market and runs quarterly legal-talent surveys since 2019 against a global set of nearly 1.5 million lawyer profiles. City findings below come from that Seattle program: 17 closed In-House Commercial Counsel Recruiting searches over three years, offer-to-acceptance windows, and counter-offer incidence. We cannot see a second employer-published diagnostics counsel band in Seattle.
Dated public filings include Adaptive's 1 July 2026 Counsel listing and 2025 Form 10-K, Adaptive's 29 July 2026 Q2 results, Life Science Washington's 2026 Economic Impact Report, the Washington Attorney General's My Health My Data Act materials, and Adaptive's 15 June 2026 MRD separation announcement. Named employers appear only in landscape prose; case studies stay anonymized by company type.
In-house commercial counsel timelines of 8 to 16 weeks, 12 working days from offer to acceptance, and 29% counter-offer incidence are Sartori Seattle program constants for this search line. Completion on the 17 files sat at 94%. A head of legal recruiting at a Seattle life-science employer told us that diagnostics commercial seats failed when the first term sheet was cash-only. That read matches the 5 stalled files in our 36-month telemetry.
Hiring in Seattle?
Whether you are building a team or weighing a move, we listen first. No obligation.
08 — Sources
09 — Questions
Seattle has no verified ranking of diagnostics counsel recruiters. What can be checked is coverage of the market, stated method and the record on closed searches. Sartori & Partners maps roughly 8,500 lawyers in Seattle and has worked this market for 8 years. Over the trailing three years we closed 17 in-house commercial counsel recruiting searches here at a 94% completion rate, with a median timeline of 8 to 16 weeks. Across 250 structured interviews with Seattle in-house counsel over 36 months, Sartori found 44% said diagnostics commercial packages hinged on equity vesting and bonus eligibility after cash. A head of legal recruiting at a Seattle life-science employer told us that diagnostics commercial seats failed when the first term sheet was cash-only. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
They price a 2026 Counsel package of $172,000–$258,000 cash plus bonus eligibility and an equity grant. Adaptive Biotechnologies disclosed that shape on 1 July 2026 for a Seattle-based commercial diagnostics seat. Employers here do not publish a second local band.
Sartori's Seattle median for this in-house line is 8 to 16 weeks. Offer-to-acceptance on our files is 12 working days once equity sits next to cash. Counter-offer incidence on the same line is 29%.
Adaptive Biotechnologies hired for Counsel in 2026 among a set that also includes Tasso, InBios, Immunexpress, TwinStrand, Bruker, and Roche Stratos. Adaptive's 2025 Form 10-K records 624 employees and a Seattle CLIA laboratory for clonoSEQ. InBios announced a $16,511,354 BARDA award in 2024; that is adjacent government-contract work, not a live legal requisition.
Laboratory services agreements, EMR integrations, privacy addenda, and FAR/DFARS terms sat at the center of the 2026 Adaptive Counsel brief. Q2 2026 clonoSEQ volume of 36,111 tests is the commercial stack those contracts must keep up with. Washington's My Health My Data Act has treated diagnostic testing as consumer health data since 31 March 2024.
Adaptive delivered 36,111 clonoSEQ tests in Q2 2026, up 43% year on year. Full-year MRD guidance moved to $268–$278 million, so laboratory services and EMR contract load did not reverse. A chief legal officer still needs that commercial capacity in Seattle.
Related
In-house & general counsel · All services · Locations · Practice areas
